Exercise booster? CoQ10 may help kidney patients build muscle

NCT ID NCT05422534

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding CoQ10 (a supplement that supports cell energy) to high-intensity interval training can help people with end-stage kidney disease build muscle and improve physical function. 156 adults on dialysis will be assigned to exercise alone or exercise plus CoQ10. The goal is to see if targeting mitochondria can make exercise more effective for preventing frailty.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 156 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects age 18 to 75 years * On thrice-weekly chronic hemodialysis for at least 6 months (only applicable for patients with ESRD on maintenance hemodialysis). * Clinically stable, adequately dialyzed (single-pool Kt/V \>1.2) thrice weekly, for at least 3 consecutive months prior to the study (only applicable for patients with ESRD on maintenance hemodialysis) Exclusion Criteria: * Body mass index \> 35 mg/kg2 * History of functional transplant less than 6 months prior to study * Use of immunosuppressive drugs within 1 month prior to study * Active connective tissue disease * Acute infectious disease within 1 month prior to study * AIDS (HIV seropositivity is not an exclusion criterion) * Acute myocardial infarction or cerebrovascular event within 3 months * Uncontrolled blood pressure * New or worsening mitral regurgitation murmur * Hypotension, bradycardia, or tachycardia * Prolonged ongoing (greater than 20 minutes) angina at rest * Angina at rest with transient ST changes greater than 0.05 mV on ECG * Sustained ventricular tachycardia on ECG * Elevated cardiac enzymes (e.g., troponin Tor I greater than 0.1mg/ml) * Advanced liver disease, with a modified Child-Turcotte-Pugh score equal or greater than 10. * Gastrointestinal dysfunction requiring parental nutrition * Active malignancy excluding basal cell carcinoma of the skin * Ejection fraction less than 30% * Pre-dialysis potassium repeatedly higher than 5.5 mmol/L (confirmed on a repeated blood draw) * Anticipated live donor kidney transplant * History of poor adherence to hemodialysis or medical regimen * Inability to provide consent * Subjects with cardiac pacemaker, artificial heart valve, any metallic implant, permanent tattoo, or any retained foreign metallic bodies. * Inability to perform exercise * Contraindication for exercise such as electrolyte abnormalities, uncontrolled arrhythmias, or pulmonary congestion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage renal disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California Davis Health

    NOT_YET_RECRUITING

    Sacramento, California, 95817, United States

  • Vanderbilt University Medical Center-GCRC

    RECRUITING

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.